N-metil-?-(2-metilfenoxi) -,

Code ATC
N06 BA09
C17 H21 NO
Molecular weight 255,36 g/mol
Metabolism , via CYP2D6
Approx. 5 hours
Legal status Sale under prescription (EE.UU.) </br>

: </br> List IV ()

Administration Oral (capsules 5, 10, 18, 25, 40 and 60 mg)

atomoxetina she is an agent neurotónico, indicated exclusively for the treatment of ADHD. Although usually it is classified like antidepressant, it does not have studied and proven clinical effects for that intention. The main criterion to include it in that farmacológica class is based on the absence of discriminativas properties of type , which are characteristic of traditional medications for ADHD. Nevertheless, in agreement with the criteria of codification ATC, the atomoxetina Integra the farmacológico group of stimulating and nootrópicos and, more specifically, it belongs to the family of . However, one is a substance whose profile is novel and difficult to categorizar, to that attribute selective activantes properties on executive functions and the cognition, [ 1 ] and that has demonstrated to harness the implied inhibiting mechanisms in the control of the impulsivas conducts.

Table of contents


The atomoxetina is a selective inhibitor of the recaptación of . It acts inhibiting the transport of the adrenérgica neuroamina at level presináptico. It is indicated for the treatment of the conductuales disorders (nervous hyperactivity) and/or the associated disatencionales syndromes to , in children, adolescents and adults.


The atomoxetina is absorbed after its administration by oral route being easily little affected by the meals. Its biodisponibilidad is of 63%, its average life is of 5 hours, its protein tie is extensive (98%). It undergoes a process of metabolic biotransformación by the CYP2D6 and is for that reason that its association with inhibitors of this isoenzima like paroxetina, and quinidona they would increase the séricos levels of atomoxetina forcing to an adjustment posológico. The main formed metabolito is the 4-hidroxiatomoxetina O-glucurónico that is of smaller activity than the drug mother and is eliminated in his greater proportion by tinkles (80%) and the rest by lees.

Precautions and warnings

The atomoxetina must be used with precaution in carrying patients of arrhythmias (tachycardia), arterial hypertension or cardiovascular pathologies since it can cause increase of the cardiac frequency and the pressure arterial. Due to this effect its association will be due to evaluate carefully with presoras amines. The security of its use in children has not settled down minors of 6 years. Its use is contraindicated in patients with glaucoma of close angle.

Adverse reactions

Occasionally allergic reactions have appeared (urticaria, rash cutaneous, edema angioneurótico), gastric loss of the appetite, migraines, problems. Recently, the appearance of severe depressive episodes and isolated cases of hepatotoxicidad has been reported, associated with the administration of the drug. The correlation has not been established of conclusive way and still he is preliminary.


The simultaneous administration of the atomoxetina with drugs that act on isoenzima CYP2D6 inhibiting it (paroxetina, and quinidina) can increase the concentrations plasmáticas of the same one. The concomitante use with the broncodilatador salbutamol can increase to the cardiotónicos and vasopresores effects of the stimulation adrenérgica beta-2. Atomoxetina with drugs IMAO and the treatment will only be able to be initiated once passed 15 days from the suspension of the antidepressant is not due to associate.

It also see

External liaisons

and Nootrópicos to publish

Adrafinil DMAE Piracetam Prolintano Sulbutiamina

to publish

Atomoxetina Fencanfamina Fenozolona Mazindol Sibutramina


  > Spanish to English > (Machine translated into English)